Central orexin-A augments sympathoadrenal outflow in conscious rabbits.
We determined the cardiovascular and neurohormonal responses to intracerebroventricular administration of orexin-A in conscious rabbits. Intracerebroventricular injection of orexin-A elicited dose-related increases in mean arterial pressure and renal sympathetic nerve activity. Peak values of mean arterial pressure and renal sympathetic nerve activity induced by intracerebroventricular injection of 100 pmol of orexin-A (14.0+/-0.7 mm Hg and 55.4+/-14.9%, respectively) were obtained at 40 and 25 minutes after injection, respectively. Plasma epinephrine and glucose concentrations were significantly increased at 60 and 90 minutes after intracerebroventricular injection of orexin-A (control versus 90 minutes; for epinephrine, 38.0+/-12.8 versus 167.5+/-42.5 pg/mL, P<0.01; for glucose, 6.66+/-0.18 versus 7.75+/-0.14 mmol/L, P<0.01). Plasma norepinephrine and insulin concentrations increased at 60 and 90 minutes but did not attain significant values. Intracerebroventricular injection of orexin-A also caused significant increases in plasma vasopressin concentrations. However, pretreatment with an intravenous injection of pentolinium (5 mg/kg), a ganglion-blocking agent, abolished these cardiovascular and neurohormonal responses. On the other hand, intravenous injection of the same dose of orexin-A (100 pmol) used in the intracerebroventricular experiment failed to cause any cardiovascular and renal sympathetic nerve responses. These results suggest that intracerebroventricular orexin-A acts in the central nervous system and activates sympathoadrenal outflow, resulting in increases in arterial pressure and plasma glucose levels in conscious rabbits.
Matsumura
K
K
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. matsumk@intmed2.med.kyushu-u.ac.jp
Tsuchihashi
T
T
Abe
I
I
D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure / Q000187:drug effects; D002352:Carrier Proteins / Q000494:pharmacology*; D002552:Cerebral Ventricles; D004305:Dose-Response Relationship, Drug; D004837:Epinephrine / Q000097:blood*; D005730:Ganglionic Blockers / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects; D007328:Insulin / Q000097:blood; D047908:Intracellular Signaling Peptides and Proteins; D007668:Kidney / Q000294:innervation; D008297:Male; D009479:Neuropeptides / Q000494:pharmacology*; D009638:Norepinephrine / Q000097:blood; D000068797:Orexins; D010425:Pentolinium Tartrate / Q000494:pharmacology; D011817:Rabbits; D013566:Sympathomimetics / Q000494:pharmacology*; D014667:Vasopressins / Q000097:blood
D001786:Blood Glucose; D002352:Carrier Proteins; D005730:Ganglionic Blockers; D007328:Insulin; D047908:Intracellular Signaling Peptides and Proteins; D009479:Neuropeptides; D000068797:Orexins; D013566:Sympathomimetics; D014667:Vasopressins; D010425:Pentolinium Tartrate; D009638:Norepinephrine; D004837:Epinephrine